A GBI Research report reveals that the market for diabetes complication will undergo improvements and changes brought about by greater awareness and diversity.
Titled ‘Frontier Pharma: Diabetic Complications – Innovative and Diverse Neuropathies, Nephropathy and Retinopathies Pipelines Demonstrate Shift Towards Disease Modifying Therapies‘, the report details that innovative first-in-class products comprise 30% of the diabetes market’s pipeline.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The treatment options of diabetic complications currently comprise therapies that symptomatically treat the condition and aid in slowing down the disease advancement.
The existing scenario is undergoing a transformation as understanding of the disease pathophysiology is improving. This has given rise to a need for better therapeutic options that successfully align with the disease pathophysiology and focus on new targets.
Avastin (bevacizumab) and Rituxan (rituximab), used in the treatment of diabetic macular oedema and diabetic neuropathy respectively, are examples of commercially successful first-in-class products.
High-risk programmes associated with first-in-class products continue to garner interest, despite the fact that many first-in-class products fail in the market even after gaining regulatory approvals.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe GBI Research report mentions that the metabolic product pipeline has 31.7% first-in-class products, which is higher than the diabetic neuropathies space. The early pipeline of diabetic retinopathies offers many innovative products, indicating that a higher proportion of first-in-class products will be in Phase III.
Development in the diabetic complications market has been supported by deal activity with 81 licensing deals and 36 co-development deals having taken place since 2006.
Firas Nour, associate analyst for GBI Research, concludes: "The deals in diabetic complications revealed that licensing deals did not reflect the industry-wide trend of first-in-class deals being more valuable.
"Co-development deals, meanwhile, were representative of the overall picture of the complications pipeline, reflecting the shift towards therapies that are more aligned with the underlying disease pathophysiology."
